Menu Search
Equities

Merit Medical Systems Inc

MMSI:NSQ

Merit Medical Systems Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)104.92
  • Today's Change-0.41 / -0.39%
  • Shares traded565.30k
  • 1 Year change+45.08%
  • Beta0.8511
Data delayed at least 15 minutes, as of Nov 25 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy4
Outperform5
Hold2
Sell0
Strong Sell0

Share price forecast in USD

The 11 analysts offering 12 month price targets for Merit Medical Systems Inc have a median target of 109.00, with a high estimate of 125.00 and a low estimate of 103.00. The median estimate represents a 3.89% increase from the last price of 104.92.
High19.1%125.00
Med3.9%109.00
Low-1.8%103.00

Earnings history & estimates in USD

On Oct 30, 2024, Merit Medical Systems Inc reported 3rd quarter 2024 earnings of 0.86 per share. This result exceeded the 0.80 consensus of the 10 analysts covering the company and exceeded last year's 3rd quarter results by 14.67%.
The next earnings announcement is expected on Feb 26, 2025.
Average growth rate+4.01%
Merit Medical Systems Inc reported annual 2023 earnings of 3.01 per share on Feb 28, 2024.
Average growth rate+20.51%
More ▼

Revenue history & estimates in USD

Merit Medical Systems, Inc. had 3rd quarter 2024 revenues of 339.85m. This bettered the 334.62m consensus of the 11 analysts covering the company. This was 14.21% above the prior year's 3rd quarter results.
Average growth rate+1.92%
Merit Medical Systems, Inc. had revenues for the full year 2023 of 1.26bn. This was 9.24% above the prior year's results.
Average growth rate+6.18%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.